Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Atsushi Nakajima, Yuichiro Eguchi, Keizo Anzai – 16 June 2021 – Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined.